- Home
- ENLT vs AKRO Comparison
ENLT vs AKRO Comparison
Compare ENLT & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ENLT | AKRO |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 4.5B |
| IPO Year | 2023 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ENLT | AKRO |
|---|---|---|
| Price | $39.50 | $54.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 11 |
| Target Price | $37.50 | ★ $73.56 |
| AVG Volume (30 Days) | 30.2K | ★ 2.4M |
| Earning Date | 11-12-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 132.72 | N/A |
| EPS | ★ 0.96 | N/A |
| Revenue | ★ $457,756,000.00 | N/A |
| Revenue This Year | $355.90 | N/A |
| Revenue Next Year | $42.83 | N/A |
| P/E Ratio | $40.46 | ★ N/A |
| Revenue Growth | ★ 27.72 | N/A |
| 52 Week Low | $14.01 | $21.34 |
| 52 Week High | $42.38 | $58.40 |
Technical Indicators
Market Signals| Indicator | ENLT | AKRO |
|---|---|---|
| Relative Strength Index (RSI) | 52.68 | 68.63 |
| Support Level | $37.50 | $54.30 |
| Resistance Level | $40.60 | $54.70 |
| Average True Range (ATR) | 1.05 | 0.17 |
| MACD | -0.32 | -0.10 |
| Stochastic Oscillator | 30.51 | 71.07 |
Price Performance
Historical ComparisonAbout ENLT Enlight Renewable Energy Ltd.
Enlight Renewable Energy Ltd develops, finances, constructs, owns, and operates utility-scale renewable energy projects. The company's operating segments are the MENA segment, Europe segment, U.S.A segment, and Others. It generates the majority of its revenue from the Europe segment, which produces its revenue from the sale of the electricity that is produced through wind energy and solar energy in Europe.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.